Skip to main content
Premium Trial:

Request an Annual Quote

Lucigen Receives $187K Grant from Michael J. Fox Foundation

NEW YORK (GenomeWeb News) – Lucigen today announced it has received a $187,000 grant from the Michael J. Fox Foundation to study a protein that has been implicated in Parkinson's disease.

Research will be directed at LRRK2, a protein found throughout the brain. Lucigen said that researchers are particularly interested in how LRRK2 responds to different drug compounds. Small chemical compounds that may inhibit this enzyme may be useful in shedding light on the mechanisms of Parkinson's and ultimately lead to effective treatments for the disease.

The goal of the grant is to develop an inexpensive, high-throughput method for screening compounds that may inhibit LRRK2.

"This grant enables Lucigen to utilize our core strengths in protein engineering, along with a proprietary fluorescent protein previously isolated by Lucigen, in order to advance medical research into a devastating disease," David Mead, CEO of the company, said in a statement.

The Middleton, Wis.-based firm said that several new research positions have been added as part of the grant.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.